Exact Sciences Q4 Loss Narrows As Revenues Gain

Exact Sciences reported Q4 2025 revenue of $878.4 million, up from $713.4 million a year earlier, and narrowed its Q4 net loss to $86.0 million (−$0.45/share) versus a $864.6 million loss ($4.67/share) in Q4 2024. For full-year 2025 revenue rose to $3.25 billion from $2.76 billion and net loss tightened to $207.9 million ($1.10/share) versus $1.02 billion ($5.59/share) in 2024, a material improvement in profitability that could support revaluation of the stock (closed $103.24).

Analysis

Market structure: Exact Sciences (EXAS) is capturing share in the at-home colorectal screening market as evidenced by Q4 revenue up 23% YoY to $878m and FY revenue to $3.25bn, while losses compressed dramatically (Q4 loss $86m vs $864.6m). Winners are EXAS, labs/fulfillment partners (scale drives unit economics) and long-biotech income investors; losers would be smaller stool-DNA entrants and high-cost liquid-biopsy plays if payors favor lower-cost screening. Cross-asset: credit spreads on EXAS should tighten modestly (improved loss trajectory), reducing CDS tail risks; implied equity vols may compress over 3–6 months if guidance stays positive.

Risk assessment: Tail risks include a CMS reimbursement cut (>10% reduction) or adverse FDA/coverage decisions that could remove scale economics — both low probability but binary and able to erase >30% market cap. Immediate (days) reaction risk is muted post-release; short-term (weeks–months) depends on guidance and Medicare updates; long-term (quarters) driven by test adoption and margin expansion. Hidden dependencies: lab capacity, reagent supply chains, and third-party payer contract renewals; catalysts include CMS announcements (next 30–90 days) and margin guidance in next two quarters.

Trade implications: Direct bullish: selective long EXAS with defined risk (see decisions) to play margin leverage; pair trade long EXAS / short Guardant Health (GH) to isolate screening vs liquid-biopsy disappointment over 6–12 months. Options: use calendar or vertical call spreads to buy upside while capping premium if implied vol collapses; consider selling covered calls after acquisition of stock to monetize theta. Rotate 1–2% from broad biotech ETF (IBB) into diagnostics/near-term-profitability names like EXAS over next 3–9 months.

Contrarian angles: Consensus may underweight sustainable free-cash-flow conversion — if EXAS sustains ~15–20% revenue growth and drives gross margins up 300–500bps, EPS breakeven could arrive within 4 quarters and multiple expansion to 15–18x CY26 EBITDA is possible. Overdone risks: market may be pricing permanent reimbursement cuts; underdone: speed of margin recovery and cross-sell into other screening channels. Historical parallel: Illumina's re-rating after sequencing cost curve proved durable — similar re-rating possible if EXAS proves unit economics at scale. Unintended consequence: aggressive bullish positioning before payer confirmations risks a >20% drawdown on adverse CMS signals.

Key Decisions for Investors

• Establish a 2–3% long position in EXAS at market (~$103) as a core position for 6–12 months, target $140 (≈+35%) and set a hard stop-loss at -12% (~$90) to limit binary reimbursement/litigation downside.
• Implement a bullish options trade: buy a Nov 2026 110/150 call vertical (debit spread) sized to equal 1–1.5% notional exposure to cap premium, breakeven if EXAS > ~115 by Nov 2026; exit or roll if implied vol drops >30% or if EXAS reaches $150.
• Pair trade: go long EXAS 2% and short Guardant Health (GH) 1–1.5% sized by dollar exposure to hedge market beta and isolate screening-share gains; hold 6–12 months or until CMS/payer clarity arrives.
• Reduce biotech-ETF (IBB) exposure by 1–2% and redeploy into diagnostics/near-profitability names (EXAS) to tilt toward companies where improving cash generation can drive multiple expansion over 3–9 months.
• Monitor CMS reimbursement signals and major payer contract announcements over the next 30–90 days; if a payer reduces stool-DNA reimbursement by >10%, liquidate long EXAS exposure above the stop-loss level and move to cash/protective puts.